<DOC>
	<DOCNO>NCT00428662</DOCNO>
	<brief_summary>Coronary artery disease ( CAD ) large cause death disability world . Besides medicine , principle treatment condition require open narrowed artery , responsible angina symptom disease , angioplasty surgery . Introduction metal scaffold call 'stents ' past decade revolutionise angioplasty technique , make popular treatment today CAD . However stents prone becomin narrow obstruct implanataion , cause symptom non-fatal heart attack patient . Introduction stents slowly release drug locally minimize process , call 'drug-eluting stent ' ( DES ) past year one big breakthrough field cardiology . However ven current available DES still prone narrowing high-risk patient , like diabetes , also high chance sudden blockage blood clot even many year later insertion . Thus important develop technology efficacious safer DES.This include safe drug , good stent design delivery , inert platform drug release We hypothesise new stent make nanoporous particle well polymer drug release prove safe efficacious alternative currently available DES .</brief_summary>
	<brief_title>Evaluation New Nanotechnology Based Drug-Eluting Stent Opening Narrowed Arteries Heart</brief_title>
	<detailed_description />
	<mesh_term>Coronary Stenosis</mesh_term>
	<mesh_term>Paclitaxel</mesh_term>
	<criteria>1 . Male nonpregnant female 2 : 18 year age ( note : female child bear potential must negative pregnancy test within 7 day treatment must use effective pregnancy avoidance 6 month angiogram complete ) 2 . Have chest pain consistent angina pectoris history document myocardial infarction document silent ischemia 3 . Treatment native vessel de novo coronary lesion ( 1 single study lesion/patient ) 4 . Target vesseI2.5mm4.0mm diameter ( visual estimate ) 5 . Target lesion length : : : 12mm ( visual estimate ) 6 . Target lesion stenosis &gt; 50 % &lt; 100 % ( visual estimate ) 7 . At least TIMI grade II coronary flow 8 . Acceptable candidate CABG surgery 9 . Patient willing come back followup evaluation include repeat cardiac catheterization 57 month treatment 10 . Patient must provide write informed consent prior index procedure use form approve local Ethics Committee 1 . Patient experience acute myocardial infarction ( Q wave nonQ wave ) within 72 hour prior index procedure CK enzymes 2 : 2x local laboratory upper limit normal , presence CK MB level elevate local laboratory upper limit normal ; 2 . Unprotected leave main coronary disease &gt; 50 % stenosis ; 3 . Significant ( &gt; 50 % ) stenosis proximal distal target lesion might require revascularization impede runoff ; 4 . Ostial location target lesion ; 5 . Angiographic evidence thrombus within target lesion ; 6 . Severely calcified'lesion successfully predilated ; 7 . Documented L VEF &lt; 25 % , clinically significant congestive cardiac failure ; 8 . Totally occluded vessel ; 9 . Impaired renal function ( creatinine &gt; 0.27mmol/L ) time treatment ; 10 . Pretreatment device balloon angioplasty ; 11 . Excessive tortuosity proximal lesion make stent delivery deployment uncertain ; 12 . Target lesion involve bifurcation include diseased side branch &gt; 2.5mm diameter would require treatment ; 13 . Prior stenting within 5mm target lesion ; 14 . Patient recipient heart transplant ; 15 . Patient life expectancy &lt; 12 month ; 16 . Known allergy clopidogrel bisulfate ( Plavix @ ) , ticlopidine ( Ticlid @ ) , Cobalt Chromium alloy Paclitaxol medically manage ; 17 . In investigator 's opinion , significant medical condition may interfere patient 's optimal participation study ; 18 . Currently participate investigational drug device study complete primary endpoint ; 19 . Intervention another coronary lesion occur within 30 day plan within 30 day index procedure . 20 . In investigator 's opinion , lesion suitable stenting</criteria>
	<gender>All</gender>
	<minimum_age>18 Years</minimum_age>
	<maximum_age>70 Years</maximum_age>
	<verification_date>January 2007</verification_date>
	<keyword>coronary stenting</keyword>
	<keyword>drug elute stent</keyword>
	<keyword>paclitaxel</keyword>
	<keyword>nanoporous</keyword>
</DOC>